Lifitegrast

利非司特

Report date: 2026/05/15 20:01:45
NMEFirst In Class

Base Information

Drug NameLifitegrast
Drug Alias Name立泰司特lifitegrastum立他司特lifitegrastXiidra +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIntegrin alpha-L/beta-2 (LFA-1) antagonists
TargetsIntegrin alpha-L/beta-2 (LFA-1)
Therapy Area/IndicationsDiabetic macular oedemaGraft vs Host DiseaseDry Eye Syndromes +[6] 
Global Approved IndicationsDry Eye SyndromesXerophthalmia
Approved Indications in ChinaXerophthalmia
Original Approved Country/TerritoryUnited States
Original Approved Date2016/07/11
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShire Development Llc
China Registration ClassN/A

Develop Information

Active CompaniesBausch & LombNovartis Pharma AgChengdu Kanghong Pharmaceutical Group Co Ltd +[6] 
Inactive CompaniesSarcode Bioscience IncShireJohns Hopkins University +[4] 
Active IndicationsGraft vs Host DiseaseDry Eye SyndromesXerophthalmia
Inactive IndicationsDiabetic macular oedemaKeratoconjunctivitis SiccaConjunctivitis, Allergic

Other Information

ATC CodeS01XA25
Related LinksWikipediaDrugBankKEGG